Envoy Medical Stock Price, News & Analysis

Envoy Medical (NASDAQ: COCH) announced issuance of Australian Patent No. 2022229818 on October 16, 2025 for a "Cochlear Implant System with Improved Input Signal-To-Noise Ratio." The patent covers a sensor and powered signal modifier that amplifies the input at the source to reduce noise and interference.

The company highlighted its multi‑decade investment (about $300 million), prior FDA Breakthrough Device Designation for the Acclaim cochlear implant, and an ongoing U.S. pivotal clinical trial for the investigational fully implanted cochlear implant.

Envoy Medical (NASDAQ: COCH) announced completion of the first set of activations in the final stage of its pivotal clinical study for the investigational fully implanted Acclaim cochlear implant on December 10, 2025.

The company said activations occurred at two of seven investigational sites, reported no serious adverse events, and noted the study remains open with full enrollment expected in early 2026. The Acclaim device is fully implanted, uses an implanted piezoelectric sensor, has no external components or implanted magnet, and offers ~4–5 day battery between charges plus a removable battery pack.

Envoy Medical (NASDAQ: COCH) will host a fireside chat on Thursday, December 11, 2025 at 4:30 P.M. ET featuring CEO Brent Lucas and Craig Eggert, the first patient to receive the Acclaim cochlear implant.

The event includes a live question-and-answer session and will be webcast. A recording will be posted on Envoy Medical's Investor Relations website after the presentation. Investors may join the company's email distribution list by emailing Envoy@kcsa.com with COCH in the subject line.

Webcast: https://ir.envoymedical.com/news-events/ir-calendar

Envoy Medical (NASDAQ: COCH) announced the grant of its 40th active U.S. patent, U.S. Patent No. 12,485,288, covering cochlear implant stimulation calibration that enables real-time measurement and adjustment of electrical current to the auditory nerve.

The company says this adds to a portfolio that includes 45 issued foreign patents. Envoy notes its Acclaim cochlear implant received Breakthrough Device Designation (FDA, 2019) and is currently under investigation in a U.S. pivotal clinical trial.

Envoy Medical (NASDAQ: COCH) announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,465,754 on November 11, 2025 for a "Combination Implant System with Removable Earplug Sensor and Implanted Battery."

The patent covers an implantable stimulator with rechargeable energy storage paired with a removable earplug that receives power, contains a sensor and signal processor, and transmits stimulation signals to the implant. Envoy says the patent expands its intellectual property around fully implanted cochlear technology and complements progress in its pivotal Acclaim cochlear implant clinical trial. The Acclaim device holds FDA Breakthrough Device Designation (2019) and is under investigation in a U.S. pivotal trial.

Envoy Medical (NASDAQ: COCH) announced on November 18, 2025 that the first 10 patients in the pivotal Acclaim fully implanted cochlear implant trial completed their six-month follow-up visits with no serious adverse events reported.

The update notes recent trial expansion, accelerating enrollment, new patent issuances, and that Acclaim holds FDA Breakthrough Device designation (2019). The device remains investigational and is being evaluated in a U.S. pivotal trial ahead of a planned FDA submission and potential commercialization.

Envoy Medical (NASDAQ: COCH) reported a transformational Q3 2025 and subsequent events on November 10, 2025. Key corporate actions included extinguishing $32 million of debt, expanding its patent portfolio with multiple new issuances, and reaching clinical three-month follow-up milestones.

Subsequent to quarter end the company received FDA approval to expand its pivotal trial to the final stage, enrolled the first three patients in that stage, and announced closing of a registered direct offering for up to $16 million. Q3 net revenue was $42,000 and cash was approximately $3.556 million as of September 30, 2025.

Envoy Medical (NASDAQ: COCH) announced on November 4, 2025 that the first three patients have been enrolled and implanted in the final stage of the pivotal U.S. trial for the fully implanted Acclaim cochlear implant. Those initial surgeries were performed at two of seven U.S. investigational sites.

The final stage will implant 46 patients in total; 43 spots remain. The Acclaim device, engineered to operate without external wearable components, received FDA Breakthrough Device Designation in 2019 and remains under investigation. Management said faster enrollment supports progress toward FDA submission and potential commercialization.

Envoy Medical (NASDAQ: COCH) marked the three-year anniversary of the first fully implanted cochlear implant, first implanted on October 24, 2022. The company noted positive patient reports from three Early Feasibility Study (EFS) participants and said all three surpass three years post‑implant.

Envoy said it received FDA permission to expand its pivotal clinical trial into the second and final stage and holds a Breakthrough Device Designation. The pivotal Acclaim cochlear implant study is enrolling at multiple U.S. sites, and Envoy emphasizes U.S.‑based headquarters and manufacturing.